AstraZeneca Reports Phase 3 extension Data for Glofitamab in Head and neck squamous cell carcinoma

AstraZeneca today announced Phase 3 extension results for Glofitamab in patients with Head and neck squamous cell carcinoma. The study demonstrated that Glofitamab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Head and neck squamous cell carcinoma and support the continued development of Glofitamab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Glofitamab was consistent with previous observations, with no new safety signals identified.